This clinical trial is focused on studying Chronic Kidney Disease (CKD) in patients who have high levels of protein in their urine, a condition known as High Proteinuria. The study is testing a new treatment that combines two medications: Zibotentan and Dapagliflozin. These medications are taken together in a single pill, known as a fixed-dose combination, and will be compared to taking Dapagliflozin alone. The purpose of the study is to see if the combination of these two medications can better slow down the decline in kidney function compared to using Dapagliflozin by itself.

Participants in the study will be randomly assigned to receive either the combination of Zibotentan and Dapagliflozin or Dapagliflozin alone. Some participants may receive a placebo. The study will last for about 24 months, during which time participants will take the medication orally, in the form of a film-coated tablet. Throughout the study, participants will have regular check-ups to monitor their kidney function and overall health. The main focus will be on changes in kidney function over time, as well as other health indicators related to kidney disease.

This study aims to provide valuable information on whether the combination of Zibotentan and Dapagliflozin can offer better protection for the kidneys in people with Chronic Kidney Disease and High Proteinuria. By participating, individuals will contribute to research that could lead to improved treatments for this condition in the future.